Uvlrx Therapeutics Financing
Uvlrx Therapeutics, Inc., Corporation just had published form D announcing $4.00 million equity financing. This is a new filing. Uvlrx Therapeutics was able to fundraise $206,000 so far. That is 5.15% of the financing round. The total private financing amount was $4.00 million. This form was filed on 2016-11-03. The reason for the financing was: unspecified. The fundraising still has about $3.79 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Uvlrx Therapeutics is based in California. The filler’s business is Other Health Care. The SEC form was filed by Scott Grizzle CFO. The company was incorporated more than five years ago. The filler’s address is: 200 E. Carrillo St., Ste 101, Santa Barbara, Ca, California, 93101. Michael Harter is the related person in the form and it has address: 200 E. Carrillo St., Ste 101, Santa Barbara, Ca, California, 93101. Link to Uvlrx Therapeutics Filing: 000154605916000003.
Analysis of Uvlrx Therapeutics Offering
On average, startups in the Other Health Care sector, sell 68.60% of the total offering amount. Uvlrx Therapeutics sold 5.15% of the offering. The financing is still open. The average fundraising size for companies in the Other Health Care industry is $1.16 million. The offering was 82.24% smaller than the average of $1.16 million. Of course this should not be seen as negative. Firms get financed for different reasons and needs. The minimum investment for this fundraising was set at $10000. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Uvlrx Therapeutics Also
The Form D signed by Scott Grizzle might help Uvlrx Therapeutics, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.